The life sciences company IGEA Pharma N.V. is a public limited liability company (naamloze vennootschap) organized under the laws of the Netherlands, with corporate seat in Amsterdam, the Netherlands. IGEA Pharma N.V. is the ultimate parent company of the IGEA group (the "Group" or "IGEA"), consisting of three group companies (and one branch). The Group has its focus on products and services related to the prevention of Alzheimer's disease and Diabetes Type II. In this field, IGEA has finalized the development and started the commercialization of a laboratory test and a dietary supplement for the use of prevention of Alzheimer's disease and expects to launch products and services relating to the prevention of Diabetes Type II by the second half of 2019. Further research and assessment of additional applications for IGEA's existing technology are ongoing. The Group's business model is, inter alia, based on the idea that Alzheimer's disease and Diabetes Type II have to be controlled by way of prevention. An observation that leads to this conclusion is that a large portion of healthcare spending is related to largely preventable chronic diseases such as Diabetes Type II and heart diseases, which makes prevention an important factor in the attempt to reduce public and private healthcare spending. Further, innovation and research are key factors of IGEA's long-term success and future growth. The Group has R&D coordination centers located in Miami FL (U.S.) and Florence (Italy) and its research initiatives and innovation processes are accompanied by its scientific advisory board comprised of experienced scientists and physicians in the field of Alzheimer's and Diabetes Type II research.